Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report published on Monday. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners raised their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP opened at $0.16 on Monday. Tonix Pharmaceuticals has a 52 week low of $0.15 and a 52 week high of $30.40. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $3.49 million, a PE ratio of 0.00 and a beta of 2.09. The stock’s 50-day moving average price is $0.50 and its 200-day moving average price is $4.45.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The business had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. As a group, equities analysts expect that Tonix Pharmaceuticals will post -34.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.